1 – 50 of 82
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Thyroid disease in ANCA-associated vasculitis : a clinical and epidemiological study
(
- Contribution to journal › Article
-
Mark
Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden
(
- Contribution to journal › Article
-
Mark
Drug exposure and subsequent diagnosis with ANCA-associated vasculitis – A population-based case- control study
2024) p.191-191(
- Contribution to conference › Abstract
-
Mark
Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)
(
- Contribution to journal › Article
-
Mark
EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update
(
- Contribution to journal › Article
- 2023
-
Mark
High risk of stroke in ANCA-Associated vasculitis-a population-based study
(
- Contribution to journal › Article
-
Mark
Can active sun exposure decrease the risk of giant cell arteritis and polymyalgia rheumatica in women?
(
- Contribution to journal › Article
-
Mark
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
(
- Contribution to journal › Scientific review
-
Mark
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction : a multicentre study
(
- Contribution to journal › Article
-
Mark
Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis : A Multinational Retrospective Study
(
- Contribution to journal › Article
- 2022
-
Mark
Myocardial infarction in ANCA-associated vasculitis- a population-based cohort-study
2022) 20th International Vasculitis and ANCA workshop(
- Contribution to conference › Abstract
-
Mark
Epidemiology and Clinical Characteristics of Adult-Onset IgA Vasculitis in Southern Sweden
2022) 20th International Vasculitis and ANCA workshop(
- Contribution to conference › Abstract
-
Mark
No evidence that sun exposure can decrease the risk of vasculitis
2022) 20th International Vasculitis and ANCA workshop(
- Contribution to conference › Abstract
-
Mark
The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis
(
- Contribution to journal › Article
-
Mark
Infection is associated with increased risk of MPO- but not PR3-ANCA associated vasculitis
(
- Contribution to journal › Article
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
-
Mark
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
(
- Contribution to journal › Article
- 2021
-
Mark
Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study.
(
- Contribution to journal › Article
-
Mark
Venous thromboembolism in ANCA-associated vasculitis : A population-based cohort study
(
- Contribution to journal › Article
-
Mark
COVID-19 and ANCA-associated vasculitis : Recommendations for vaccine preparedness and the use of rituximab
(
- Contribution to journal › Letter
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
- 2020
-
Mark
Incidence and predictors of severe infections in ANCA-associated vasculitis in a population-based cohort – preliminary results
(
- Contribution to journal › Published meeting abstract
-
Mark
International consensus on antineutrophil cytoplasm antibodies testing in eosinophilic granulomatosis with polyangiitis
(
- Contribution to journal › Article
-
Mark
2020 international consensus on ANCA testing beyond systemic vasculitis
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
(
- Contribution to journal › Article
-
Mark
Infections are associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis - a population-based case-control study from southern sweden
2019) The 19th International Vasculitis and ANCA workshop(
- Contribution to conference › Abstract
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
-
Mark
Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis
2019) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 34(2). p.301-308(
- Contribution to journal › Article
-
Mark
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
(
- Contribution to journal › Article
- 2018
-
Mark
Comment on : Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature
(
- Contribution to journal › Letter
-
Mark
Long-term outcomes of patients with Takayasu arteritis and renal artery involvement : A cohort study
(
- Contribution to journal › Article
-
Mark
Brief Report : Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein)
(
- Contribution to journal › Article
- 2017
-
Mark
Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS)
(
- Contribution to journal › Article
-
Mark
Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides
(
- Contribution to journal › Article
-
Mark
Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis : The influence of ANCA subtype
(
- Contribution to journal › Article
-
Mark
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
-
Mark
Long term azathioprine maintenance therapy in ANCA-associated vasculitis : combined results of long-term follow-up data
(
- Contribution to journal › Article
-
Mark
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
The European Vasculitis Society 2016 Meeting Report
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Letter
- 2016
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
-
Mark
ANCA-associated glomerulonephritis : Risk factors for renal relapse
(
- Contribution to journal › Article
- 2015
-
Mark
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.
(
- Contribution to journal › Article
-
Mark
Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
(
- Contribution to journal › Article
-
Mark
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
(
- Contribution to journal › Article
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article